|
1. BIOLOGIE
|
|
|
|
1.4 BIOLOGIE - TECHNOS
|
|
|
|
2.4 ETIOLOGIE - PORTABLES, ONDES E-M
|
|
|
IARC Urged To Revisit RF Risk [Microwave News]
|
|
|
|
|
|
Neither Kurt Straif, the head of IARC’s Monographs section, nor Joachim Schüz, the head of its environment and radiation section, responded to a query on the likelihood that the agency would follow through and convene a new RF assessment committee.
|
|
|
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - POUMON
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
The future hope of “flash” radiation cancer therapy [Stanford]
|
|
|
|
|
|
"We and a few other labs around the world have started to see that when the radiation is given in a flash, we see equal or better tumor killing but much better normal tissue protection than with the conventional speed of radiation," Loo said. "And if that translates to humans, that's a huge breakthrough."
|
|
|
|
|
|
|
Imaging system helps surgeons remove tiny ovarian tumors [MIT]
|
|
|
|
|
|
Using a novel fluorescence imaging system, they were able to find and remove tumors as small as 0.3 millimeters — smaller than a poppy seed — during surgery in mice. Mice that underwent this type of image-guided surgery survived 40 percent longer than those who had tumors removed without the guided system.
|
|
|
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
|
Medicare offers to partially raise payment for cancer CAR-Ts [Reuters]
|
|
|
|
|
|
CMS, which runs the federal government’s healthcare plan for seniors, issued a proposed rule raising its maximum “new technology add-on payment” (NTAP) from 50% of estimated costs to 65%, which would increase reimbursement to $242,450 from the current $186,500. But that is still far short of actual costs.
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
The Changing Landscape of Research and Development [IQVIA]
|
|
|
|
|
|
This report puts forth a proprietary Clinical Development Productivity Index that reflects changes in trial complexity, success and duration over time. Eight key trends driving change in clinical development are explored and their expected quantitative impact on productivity through 2023 are discussed.
|
|
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
U.S. biologics and biosimilars need distinguishable names [STAT]
|
|
|
|
|
|
As this landscape evolves, and interchangeable products enter the market, it will underscore the importance in the U.S. of building the capability for accurate traceability and intentional pharmacy substitution. Appropriate systems need to be in place to support this.
|
|
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
5.6 ESMO
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
6.11 PATIENTS
|
|
|
|
6.6 PUBLICATIONS
|
|
|
Should I publish in an open access journal? [BMJ]
|
|
|
|
|
|
An “author pays” publishing model is the only fair way to make biomedical research findings accessible to all, say Matthew Kurien and David S Sanders, but James J Ashton and R Mark Beattie worry that it can lead to bias in the evidence base towards commercially driven results.
|
|
|
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
Hancock: NHS must adopt new technology or it will not survive [The Telegraph]
|
|
|
|
|
|
In a foreword to the report, Matt Hancock, Health Secretary, said: “Tech transformation in the NHS directly unlocks or frees resources for just about every other improvement we want to see, from using data to help boost cancer survival rates to joining up health and care to giving clinicians back the precious gift of time."
|
|
|
|
|
|
|
6.9 CONTROVERSES
|
|
|